09/585,817

June 1, 2000

Schenk, Dale B.

PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Numb r

Filing Date

POWER	R OF ATTORNEY OR	First Name	d Inventor	Schenk, Dale B.		
AUTHORIZATION GEAGENT		Title		Prevention and Treatment of Amyloidogenic Disease		
,	-07	Group Art U	Jnit	1647		
_	- O 4	Examiner N		Turner, Sharon L.		
		Attorney Do	ocket Number	15270J-005910US		
I hereby appoint:						
_	ers at Customer Number 2035	50	-	Number Bar Code		
OR Label here Practitioner(s) named below:						
	Name		Registration Number			
	····	<u> </u>				
			"-	· · · · · · · · · · · · · · · · · · ·		
-						
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.						
Please change the correspondence address for the above-identified application to:						
	-mentioned Customer Number.	uio abovo idona.	od application to:			
OR						
Practitioners at Customer Number						
☐ Firm or						
Individual Name						
Address		Pet		Tain I		
City		50	ate	ZIP		
Country						
Telephone			ax			
I am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71.						
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Name 1	Kevin Insley, Vice President, Neuralab Limited					
Signature	Catterny 0					
Date	FEMERALY 28, 2002					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representatives) are required. Submit multiple forms if more than one signature is required, see below*.						
Total of 1 forms are submitted.						

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3202741 v1

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Afternovy Decket No. 15270 L 005010 U.S.

Attorney Docket No. 15270J-005910US

STATEMENT UNDER 37 CFR 3.73(b)						
Applicant/Patent Owner: Dale B. Schenk						
Application No./Patent No.: 09/585,817 File	ed/Issue Date: June 1, 2000					
Entitled: Prevention and Treatment of Amyloidogenic Disease						
Neuralab Limited , a corporation						
	nee, e.g., corporation, partnership, university, government agency, etc.)					
states that it is:						
. 🔀 the assignee of the entire right, title, and interest; or						
2. an assignee of less than the entitle right, title and The extent (by, percentage) of its ownership interest.	interest. est is%					
in the patent application/patent identified above by virtue of either:						
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the british that States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.						
OR						
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:						
 From: <u>Dale B. Schenk</u> To :<u>Elan Pharmaceuticals, Inc.</u> The document was recorded in the United States Patent and Trademark Office at Reel <u>012230</u>, Frame <u>0877</u>, or for which a copy thereof is attached. 						
From: Elan Pharmaceuticals, Inc. To :Neuralab Limited The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0885, or for which a copy thereof is attached.						
3. From: Elan Pharmaceuticals, Inc. To :Neuralab Limited (Nunc Pro Tunc)						
The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0893, or for which a copy thereof is attached.						
Additional documents in the chain of title are listed on a supplemental sheet						
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]						
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.						
FEGRUARY 28, 2002	Kevin Insley					
Date	Typed or printed name					
	16atemes					
	Signature \					
	Vice President \/ Title					
	HUC					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.